World Athletics has officially commenced gene testing protocols for female athletes participating in its sanctioned events, introducing a new layer of scrutiny into eligibility criteria. This initiative seeks to clarify and maintain fair competition within women’s categories, particularly concerning athletes with Differences in Sex Development (DSD). The implementation involves a multi-faceted approach to identify genetic markers that may influence physiological characteristics relevant to sports performance.
Under the new guidelines, athletes may be subject to genetic analysis through biological samples collected by designated medical personnel. These samples will be processed in accredited laboratories to detect specific genetic variations. The primary aim is to identify individuals whose natural androgen levels, particularly testosterone, fall within a range typically associated with male physiology, even if they identify as female. The testing process is designed to be comprehensive, ensuring privacy and adherence to strict ethical standards.
Should a test reveal genetic markers or physiological indicators that place an athlete outside the defined parameters for women’s competition, further medical evaluations will be conducted. This could involve endocrinological assessments and specialized consultations to confirm findings. Athletes identified as having DSD that confers a significant performance advantage in the female category may be required to meet specific conditions, such as reducing their testosterone levels to below a designated threshold, to maintain eligibility for certain events. Alternatively, they might be advised to compete in a different category, if available, or in events where such physiological advantages are deemed less impactful. The entire process includes provisions for athlete appeals and independent review, ensuring due process. This marks a significant shift in how athletic federations approach biological sex and fairness in elite sport.
